Sir, Chronic endophthalmitis after cataract surgery secondary to Ochrobactrum anthropi
We recently encountered a rare case of post-operative Ochrobactrum anthropi endophthalmitis potentially caused by percutaneous transluminal angioplasty (PTCA) prior to cataract surgery. O. anthropi has caused catheter-associated bacteraemia, osteochondritis, and pancreatic abscess.
1-3 However, we identified only a single report of O. anthropi endophthalmitis following cataract surgery in the literature. 4 A 75-year-old man was referred for chronic endophthalmitis following uneventful cataract extraction and posterior intraocular lens (IOL) placement in April 2006. Medical history included myocardial infarction and PTCA 1 year previously (3 weeks before cataract surgery). Low-grade intraocular inflammation was noted on post-operative day 9 and treated with steroid drops; yet pan-uveitis persisted for 9 months. Pars plana vitrectomy, intravitreal antibiotic injection, two anterior chamber taps, and intracameral antibiotic injection were performed; the initial tap revealed O. anthropi.
Our initial evaluation (April 2007) detected keratic precipitates on the endothelium, fine white conglomerates on the IOL, and diffuse debris in the vitreous. We performed complete capsulectomy, IOL removal, vitrectomy, and intravitreal vancomycin and amikacin injection. Vitreous and capsular bag cultures grew O. anthropi sensitive to ceftazidime, imipenem, ciprofloxacin, and trimethoprim. Therapy included intravenous Tieman and topical ciprofloxacin. The infection cleared, and vision recovered from 4/20 to 2/20 with spectacles.
Ochrobactrum anthropi sepsis usually occurs with indwelling catheters or other medical prostheses.
5 Our patient could have been infected during cataract surgery or PTCA; O. anthropi infections manifesting within 3 weeks of central venous catheter placement and within 70 days of mitral valvuloplasty have been reported. 6, 7 Our patient received PTCA 3 weeks before cataract surgery and symptoms occurred within 10 days. We assume that O. anthropi clustered in the vitreous first, then circulated to the anterior segment.
Our patient received cataract surgery at another clinic; so his blood culture results were unavailable. Sir, Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment
The antivascular endothelial growth factor aptamer pegaptanib may induce short-term regression of retinal neovascularisation secondary to diabetes. 1 We present two diabetic patients who underwent intravitreal pegaptanib for persistent retinal neovascularisation and developed the progression of a previously stable tractional retinal detachment (TRD).
Case reports

Case 1
A 26-year-old woman with severe proliferative diabetic retinopathy underwent extensive scatter laser photocoagulation (PRP) leading to the regression of neovascularisation and a localised right inferotemporal TRD.
After 6 months, the TRD appeared unchanged, but fresh vitreous and preretinal haemorrhages were observed. Informed consent was obtained for intravitreal pegaptanib (0.3 mg/0.9 ml).
Ten days after injection, the TRD appeared stable (Figure 1) . By 5 weeks, TRD progression had resulted in macular elevation and reduced visual acuity from 6/12 to 6/36 (Figure 2) .
The patient underwent vitrectomy, delamination, endolaser, and sulphur hexafluoride gas with minimal intraoperative haemorrhage. After 2 months, the visual acuity was 6/12.
Case 2
A 48-year-old woman with proliferative diabetic retinopathy underwent extensive PRP and developed TRD associated with regressed inferotemporal neovascularisation. After 8 months, active neovascularisation recurred although the TRD remained unchanged (Figure 3a and b) .
Informed consent was obtained for intravitreal pegaptanib (0.3 mg/0.9 ml). Three weeks later, although neovascularisation and preretinal haemorrhage had improved, the TRD had progressed and visual acuity reduced from 6/36 to counting fingers (Figure 4a and b) . The patient underwent right vitrectomy, delamination, and octafluoropropane gas. Minimal intraoperative haemorrhage permitted a low infusion pressure during surgery. After 6 weeks, the visual acuity was 6/12.
Comment
The preexisting TRD had remained stable for 6 months and 8 months in cases 1 and 2, respectively before progressing within the weeks of intravitreal pegaptanib. 
